Literature DB >> 28269963

Learning Effective Treatment Pathways for Type-2 Diabetes from a clinical data warehouse.

Rohit Vashisht1, Ken Jung1, Nigam Shah1.   

Abstract

Treatment guidelines for management of type-2 diabetes mellitus (T2DM) are controversial because existing evidence from randomized clinical trials do not address many important clinical questions. Data from Electronic Medical Records (EMRs) has been used to profile first line therapy choices, but this work did not elucidate the factors underlying deviations from current treatment guidelines and the relative efficacy of different treatment options. We have used data from the Stanford Hospital to attempt to address these issues. Clinical features associated with the initial choice of treatment were effectively re-discovered using a machine learning approach. In addition, the efficacies of first and second line treatments were evaluated using Cox proportional hazard models for control of Hemoglobin A1c. Factors such as acute kidney disorder and liver disorder were predictive of first line therapy choices. Sitagliptin was the most effective second-line therapy, and as effective as metformin as a first line therapy.

Entities:  

Keywords:  Learning Health Systems; Second-line treatment options; Treatment Pathways; Type-2 Diabetes

Mesh:

Substances:

Year:  2017        PMID: 28269963      PMCID: PMC5333256     

Source DB:  PubMed          Journal:  AMIA Annu Symp Proc        ISSN: 1559-4076


  15 in total

1.  STRIDE--An integrated standards-based translational research informatics platform.

Authors:  Henry J Lowe; Todd A Ferris; Penni M Hernandez; Susan C Weber
Journal:  AMIA Annu Symp Proc       Date:  2009-11-14

2.  CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY.

Authors:  Alan J Garber; Martin J Abrahamson; Joshua I Barzilay; Lawrence Blonde; Zachary T Bloomgarden; Michael A Bush; Samuel Dagogo-Jack; Ralph A DeFronzo; Daniel Einhorn; Vivian A Fonseca; Jeffrey R Garber; W Timothy Garvey; George Grunberger; Yehuda Handelsman; Robert R Henry; Irl B Hirsch; Paul S Jellinger; Janet B McGill; Jeffrey I Mechanick; Paul D Rosenblit; Guillermo E Umpierrez
Journal:  Endocr Pract       Date:  2016-01       Impact factor: 3.443

3.  Erratum. Classification and diagnosis of diabetes. Sec. 2. In Standards of Medical Care in Diabetes-2016. Diabetes Care 2016;39(Suppl. 1):S13-S22.

Authors: 
Journal:  Diabetes Care       Date:  2016-09       Impact factor: 19.112

Review 4.  Mining electronic health records: towards better research applications and clinical care.

Authors:  Peter B Jensen; Lars J Jensen; Søren Brunak
Journal:  Nat Rev Genet       Date:  2012-05-02       Impact factor: 53.242

5.  Regularization Paths for Generalized Linear Models via Coordinate Descent.

Authors:  Jerome Friedman; Trevor Hastie; Rob Tibshirani
Journal:  J Stat Softw       Date:  2010       Impact factor: 6.440

6.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

Authors:  D M Nathan; S Genuth; J Lachin; P Cleary; O Crofford; M Davis; L Rand; C Siebert
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

7.  Glucose control and vascular complications in veterans with type 2 diabetes.

Authors:  William Duckworth; Carlos Abraira; Thomas Moritz; Domenic Reda; Nicholas Emanuele; Peter D Reaven; Franklin J Zieve; Jennifer Marks; Stephen N Davis; Rodney Hayward; Stuart R Warren; Steven Goldman; Madeline McCarren; Mary Ellen Vitek; William G Henderson; Grant D Huang
Journal:  N Engl J Med       Date:  2008-12-17       Impact factor: 91.245

8.  Global estimates of the prevalence of diabetes for 2010 and 2030.

Authors:  J E Shaw; R A Sicree; P Z Zimmet
Journal:  Diabetes Res Clin Pract       Date:  2009-11-06       Impact factor: 5.602

9.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

10.  Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.

Authors:  Yoshikazu Nitta; Nobuhiro Tahara; Atsuko Tahara; Akihiro Honda; Norihiro Kodama; Minori Mizoguchi; Hayato Kaida; Masatoshi Ishibashi; Naofumi Hayabuchi; Hisao Ikeda; Sho-ichi Yamagishi; Tsutomu Imaizumi
Journal:  JACC Cardiovasc Imaging       Date:  2013-11
View more
  4 in total

1.  Quantifying Variation in Treatment Utilization for Type 2 Diabetes Across Five Major University of California Health Systems.

Authors:  Thomas A Peterson; Valy Fontil; Suneil K Koliwad; Ayan Patel; Atul J Butte
Journal:  Diabetes Care       Date:  2021-02-02       Impact factor: 19.112

2.  Preliminary exploration of survival analysis using the OHDSI common data model: a case study of intrahepatic cholangiocarcinoma.

Authors:  Na Hong; Ning Zhang; Huawei Wu; Shanshan Lu; Yue Yu; Li Hou; Yinying Lu; Hongfang Liu; Guoqian Jiang
Journal:  BMC Med Inform Decis Mak       Date:  2018-12-07       Impact factor: 2.796

Review 3.  Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease.

Authors:  Sebastian Niezen; Humberto Diaz Del Castillo; Lumen A Mendez Castaner; Alessia Fornoni
Journal:  Endocrinol Diabetes Metab       Date:  2019-05-17

4.  ROMOP: a light-weight R package for interfacing with OMOP-formatted electronic health record data.

Authors:  Benjamin S Glicksberg; Boris Oskotsky; Nicholas Giangreco; Phyllis M Thangaraj; Vivek Rudrapatna; Debajyoti Datta; Remi Frazier; Nelson Lee; Rick Larsen; Nicholas P Tatonetti; Atul J Butte
Journal:  JAMIA Open       Date:  2019-01-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.